Mirtazapine, a Mixed-Profile Serotonin Agonist/Antagonist, Suppresses Sleep Apnea in the Rat
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Serotonin enhancing drugs, including L-tryptophan and, more recently, fluoxetine and paroxetine, have been tested as pharmacologic treatments for sleep apnea syndrome. Although some patients have demonstrated reduced apnea expression after treatment with these compounds, this improvement has been restricted to nonrapid eye movement (NREM) sleep, with some patients showing no improvement. This study reports the effects of mirtazapine, an antidepressant with 5-HT(1) agonist as well as 5-HT(2) and 5-HT(3) antagonist effects, on sleep and respiration in an established animal model of central apnea. We studied nine adult male Sprague-Dawley rats chronically instrumented for sleep staging. In random order on separate days, rats were recorded after intraperitoneal injection of: (1) saline, (2) 0.1 mg/kg +/- mirtazapine (labeled as Remeron), (3) 1 mg/kg mirtazapine, or (4) 5 mg/ kg mirtazapine. With respect to saline injections, mirtazapine at all three doses reduced apnea index during NREM sleep by more than 50% (p < 0.0001) and during REM sleep by 60% (p < 0.0001) for at least 6 h. In association with this apnea suppression normalized inspiratory minute ventilation increased during all wake/sleep states (p < 0.001 for each state). The duration of NREM sleep was unaffected by any dose of mirtazapine (p = 0.42), but NREM EEG delta power was increased by more than 30% at all doses (p = 0.04), indicating improved NREM sleep consolidation after mirtazapine injection. We conclude that mirtazapine, over a 50-fold dose range, significantly reduces central apnea expression during NREM and REM sleep in the rat. The efficacy of this compound to suppress apnea in all sleep stages most probably arises from its mixed agonist/antagonist profile at serotonin receptors. The implications of these findings for the management of sleep apnea syndrome must be verified by appropriate clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of the antidepressant Org 3770 on human sleep
Ruigt, G. S. F., Kemp, B., Groenhout, C. M., & Kamphuisen, H. A. C. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00278580 · Cited by 110
Cited by
Marshall, N. S., Yee, B. J., Desai, A. V., Buchanan, P. R., Wong, K. K., Crompton, R., Melehan, K. L., Zack, N., Rao, S. G., Gendreau, R. M., et al. (2008) · Sleep · doi:10.1093/sleep/31.6.824 · Cited by 224
Serotonin Agonists and Antagonists in Obstructive Sleep Apnea: Therapeutic Potential
Veasey, S. C. (2003) · American Journal of Respiratory Medicine · doi:10.1007/bf03256636 · Cited by 129
Efficacy of mirtazapine in obstructive sleep apnea syndrome
Carley, D. W., Olopade, C., Ruigt, G. S., & Radulovacki, M. (2007) · Sleep · doi:10.1093/sleep/30.1.35 · Cited by 117
Self-citationTrazodone increases arousal threshold in obstructive sleep apnoea
Heinzer, R. C., White, D. P., Jordan, A. S., Lo, Y. L., Dover, L., Stevenson, K., & Malhotra, A. (2008) · European Respiratory Journal · doi:10.1183/09031936.00067607 · Cited by 110
Metadata
- Authors
- CARLEY, D. W., & RADULOVACKI, M.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-12-01
- Volume
- 160
- Issue
- 6
- Pages
- 1824-1829
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2027210685
- Cited by
- 76
- References
- 2
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mirtazapine, a Mixed-Profile Serotonin Agonist/Antagonist, Suppresses Sleep Apnea in the Rat. https://app.cochat.ai/papers/10.1164/ajrccm.160.6.9902090
- The paper
- CARLEY, D. W., & RADULOVACKI, M. (1999). Mirtazapine, a Mixed-Profile Serotonin Agonist/Antagonist, Suppresses Sleep Apnea in the Rat. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.160.6.9902090
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.